Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACROBAT: Azacitidine vs Standard Care in HR-MDS
NCT04184505Phase 3Recruiting
- Sponsor
- GIMEMA
- Start
- Nov 2020
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azacitidine in myelodysplastic syndrome (MDS) (2 arms), sponsored by GIMEMA. Primary endpoint: Feasibility of Allogeneic Stem Cell Transplantation at 4 years. Started Nov 2020; status: recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04184505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184505.